Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...

-- Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors -- Matthew Baker appointed as CEO -- Laigo Bio's SureTAC (TM) membrane protein degradation ...

Denali's validated platform, strategic pipeline, and experienced management present a compelling long-term investment opportunity. Find out why DNLI stock is a Buy.

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. The findings, ...

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by attaching phosphate groups to other proteins. When these switches are stuck in the ...

BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

ALBUQUERQUE, NM and MEMPHIS, TN – November 25, 2025 – Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...